Kaveri Pohlman
Stock Analyst at Clear Street
(4.34)
# 1,325
Out of 4,639 analysts
237
Total ratings
40.2%
Success rate
12.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics | Rated: Buy | $116 → $173 | $148.29 | +16.66% | 6 | Aug 6, 2026 | |
| ELVN Enliven Therapeutics | Rated: Buy | $55 → $68 | $58.78 | +15.69% | 3 | Aug 6, 2026 | |
| EQ Equillium | Maintained: Buy | $9 | $2.23 | +303.59% | 2 | Aug 3, 2026 | |
| EVMN Evommune | Maintained: Buy | $28 | $14.21 | +97.04% | 3 | Jul 16, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintained: Buy | $70 | $16.59 | +321.94% | 6 | Jun 22, 2026 | |
| CGEM Cullinan Therapeutics | Maintained: Buy | $33 → $46 | $19.63 | +134.34% | 19 | Jun 10, 2026 | |
| LBRX LB Pharmaceuticals | Initiated Coverage: Buy | $45 | $45.33 | -0.73% | 1 | May 26, 2026 | |
| SGMT Sagimet Biosciences | Maintained: Buy | $37 → $28 | $9.52 | +194.12% | 4 | May 13, 2026 | |
| TRVI Trevi Therapeutics | Maintained: Buy | $21 → $29 | $17.80 | +62.92% | 3 | May 7, 2026 | |
| MDGL Madrigal Pharmaceuticals | Maintained: Buy | $533 → $680 | $535.27 | +27.04% | 3 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $71 → $131 | $104.68 | +25.15% | 4 | Apr 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $2.14 | +460.75% | 2 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $11 → $20 | $18.31 | +9.23% | 3 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $200 → $220 | $154.30 | +42.58% | 3 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $32 → $12 | $16.52 | -27.36% | 4 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $9.75 | +84.62% | 1 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $61 → $99 | $52.13 | +89.91% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 | $22.35 | +11.86% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $5.56 | +223.74% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $6.37 | +88.38% | 17 | Nov 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $32 → $47 | $31.39 | +49.73% | 2 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $51.33 | n/a | 8 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.92 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $22.10 | n/a | 13 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $28.74 | n/a | 30 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $30.85 | n/a | 18 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $13.65 | n/a | 13 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $7.18 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.83 | n/a | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 | $3.50 | n/a | 17 | Jun 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $21 | $2.08 | n/a | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.00001 | n/a | 6 | Nov 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $16 → $8 | $3.45 | n/a | 3 | Jul 6, 2022 |
Protagonist Therapeutics
Aug 6, 2026
Rated: Buy
Price Target: $116 → $173
Current: $148.29
Upside: +16.66%
Enliven Therapeutics
Aug 6, 2026
Rated: Buy
Price Target: $55 → $68
Current: $58.78
Upside: +15.69%
Equillium
Aug 3, 2026
Maintained: Buy
Price Target: $9
Current: $2.23
Upside: +303.59%
Evommune
Jul 16, 2026
Maintained: Buy
Price Target: $28
Current: $14.21
Upside: +97.04%
MoonLake Immunotherapeutics
Jun 22, 2026
Maintained: Buy
Price Target: $70
Current: $16.59
Upside: +321.94%
Cullinan Therapeutics
Jun 10, 2026
Maintained: Buy
Price Target: $33 → $46
Current: $19.63
Upside: +134.34%
LB Pharmaceuticals
May 26, 2026
Initiated Coverage: Buy
Price Target: $45
Current: $45.33
Upside: -0.73%
Sagimet Biosciences
May 13, 2026
Maintained: Buy
Price Target: $37 → $28
Current: $9.52
Upside: +194.12%
Trevi Therapeutics
May 7, 2026
Maintained: Buy
Price Target: $21 → $29
Current: $17.80
Upside: +62.92%
Madrigal Pharmaceuticals
May 6, 2026
Maintained: Buy
Price Target: $533 → $680
Current: $535.27
Upside: +27.04%
Apr 27, 2026
Maintained: Buy
Price Target: $71 → $131
Current: $104.68
Upside: +25.15%
Mar 31, 2026
Maintained: Buy
Price Target: $12
Current: $2.14
Upside: +460.75%
Mar 6, 2026
Rated: Buy
Price Target: $11 → $20
Current: $18.31
Upside: +9.23%
Mar 2, 2026
Maintained: Buy
Price Target: $200 → $220
Current: $154.30
Upside: +42.58%
Jan 20, 2026
Downgraded: Hold
Price Target: $32 → $12
Current: $16.52
Upside: -27.36%
Dec 11, 2025
Reiterated: Buy
Price Target: $18
Current: $9.75
Upside: +84.62%
Dec 9, 2025
Maintained: Buy
Price Target: $61 → $99
Current: $52.13
Upside: +89.91%
Dec 1, 2025
Maintained: Buy
Price Target: $25
Current: $22.35
Upside: +11.86%
Dec 1, 2025
Maintained: Buy
Price Target: $18
Current: $5.56
Upside: +223.74%
Nov 26, 2025
Maintained: Buy
Price Target: $12
Current: $6.37
Upside: +88.38%
Nov 11, 2025
Maintained: Buy
Price Target: $32 → $47
Current: $31.39
Upside: +49.73%
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $51.33
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $3.92
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $22.10
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $28.74
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $30.85
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $13.65
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $7.18
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $2.83
Upside: n/a
Jun 2, 2024
Maintained: Buy
Price Target: $13
Current: $3.50
Upside: n/a
Apr 29, 2024
Maintained: Buy
Price Target: $21
Current: $2.08
Upside: n/a
Nov 23, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.00001
Upside: n/a
Jul 6, 2022
Rated: Buy
Price Target: $16 → $8
Current: $3.45
Upside: n/a